Samsung Biologics Seeks KRW 3 Trillion to Fuel Expansion and Acquisitions

The capital raise, consisting of approximately 2.27 million new common shares priced at KRW 1,322,000 each, represents a 15% discount on the reference price. The bulk of these proceeds—roughly KRW 2.71 trillion—is earmarked for the acquisition of PolyPeptide Group. By absorbing the firm, Samsung aims to move beyond its traditional stronghold in antibodies and antibody-drug conjugates into the high-demand world of peptide-based therapeutics.

Beyond the acquisition, the company is funneling KRW 290 billion into its Songdo Bio Campus II. With Plant 5 slated for completion in 2025, leadership is already evaluating the rollout of Plants 6 through 8. These additions are designed to push the company's total manufacturing capacity to 1,385,000 liters by 2032. CEO John Rim described the move as a critical step in maintaining the firm's top-tier status in the global CDMO market.

Existing shareholders will receive first rights to the new shares on a pro-rata basis, with 20% reserved for the company's employee stock ownership association. Trading of subscription rights begins ahead of the official subscription window in November, with the new shares expected to debut on the market by November 30.